- Our Company
- News & Events
- Contact Us
October marks the start of Breast Cancer Awareness Month. Earlier this year, the U.S. Food and Drug Administration (FDA) approved the Guardant360® CDx liquid biopsy test as a companion diagnostic to identify advanced or metastatic breast cancer patients with ESR1 mutations who may benefit from treatment with elacestrant. As breast cancer is the most frequently diagnosed cancer among women worldwide, this FDA approval is great news for breast cancer patients with ESR1 mutations. Elacestrant is also the first FDA-approved endocrine therapy innovation in more than 20 years, specifically addressing ESR1 mutations, a major unmet need in the treatment of metastatic breast cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer
Visit us at https://lnkd.in/gHNdYtQN to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer.
#guardanthealth #guardanthealthamea #liquidbiopsy #liquidissolid #breastcancerawarenessmonth #breastcancer #MBC #companiondiagnostic #CDx #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #medicaloncologists